Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

Cancer. 2004 Sep 15;101(6):1478; author reply 1478. doi: 10.1002/cncr.20495.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Protein Kinases / therapeutic use*
  • Sirolimus / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases

Substances

  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus